SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced that Dee Data, Ph.D., Co-Founder and CEO of Switch Therapeutics, will present a corporate overview at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 10:50 a.m. ET (7:50 a.m. PT) in New York City. Members of management will also be available for one-on-one meetings.
About Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. Switch is based in South San Francisco, California. For more information, connect with Switch on LinkedIn or visit www.switchthera.com
Contacts
Media Contact:
Tressa Frankel, Health+Commerce
tressa@healthandcommerce.com
Investor Contact:
Hannah Deresiewicz, Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com